Affimed, Medicenna, and Karuna Therapeutics in the spotlight

Sliding scales on $AFMD, $MDNA, and $KRTX

Affimed has been on a dive, now trading under $1/share. At a recent Q&A, Affimed CEO gave additional details on the IND process with FDA to get AFM13+NK cells from partner Artiva into human trials. The planned trial has 2 phases:

• Phase 1 of the trial will include 2 doses of NK cells. The lower dose will be 1 billion NK cells from Artiva and the higher do…